People: TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

24 May 2019
Change (% chg)

$0.10 (+3.25%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Bernick, Brian 

Dr. Brian Bernick, M.D., is Chief Clinical Officer, Director of TherapeuticsMD, Inc., since November 25th, 2013. He also has served as the Chief Clinical Officer of our company since November 2013, and as the Chief Medical Officer of our company from February 2012 until November 2013. As co-founder of VitaMed, Dr. Bernick served as a director of VitaMed from April 2008 to October 2011. Dr. Bernick is a board- certified obstetrician/gynecologist with over 20 years of clinical medical experience. Dr. Bernick was the Department Chair of Obstetrics and Gynecology at Boca Raton Regional Hospital and served on that hospital’s Medical Executive Board as well as the Board of Directors of the Palm Beach Medical Society and VitalMD Group Holding, LLC, one of the largest physician-owned and -managed obstetricians/gynecologists groups in Florida. Dr. Bernick has served on the American College of Obstetricians and Gynecologists’ (ACOG) national committee on Professional Liability. Dr. Bernick is the recipient of several national and regional awards, including recognition by his peers as one of the top doctor’s in his specialty by Castle Connolly as well as the recipient of the American Medical Association Foundation’s Leadership Award. Dr. Bernick has numerous publications in peer-reviewed journals and has presented original research at numerous medical conferences. Dr. Bernick is an affiliate associate professor of obstetrics and gynecology at Florida Atlantic University College of Medicine. Dr. Bernick holds a B.A. in Economics from Northwestern University, received his Doctorate in Medicine from the Chicago Medical School, and completed his residency at the University of Pennsylvania.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,297,940
Fiscal Year Total, USD 1,297,940

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Tommy Thompson


John Milligan


Robert Finizio


Daniel Cartwright


Mitchell Krassan


Michael Donegan

As Of  31 Dec 2017